#1 Clinical Trials Search in Europe

Serpina1(Human)-Aav8-1

This article discusses the clinical trials of NTLA-3001, a novel gene therapy drug using Serpina1(Human)-AAV8-1 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated lung disease. The Phase 1/2 study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of this innovative treatment in adult patients. NTLA-3001 represents a potential breakthrough in addressing the underlying cause of AATD-related lung problems.

Table of Contents

What is SERPINA1(HUMAN)-AAV8-1?

SERPINA1(HUMAN)-AAV8-1, also known as NTLA-3001, is an innovative gene therapy being developed to treat Alpha-1 Antitrypsin Deficiency (AATD)-associated lung disease. This therapy is currently undergoing clinical trials to evaluate its safety and effectiveness[1].

Gene therapy is a medical approach that involves introducing genetic material into a person’s cells to treat or prevent disease. In this case, SERPINA1(HUMAN)-AAV8-1 is designed to deliver a healthy copy of the SERPINA1 gene, which is responsible for producing the Alpha-1 Antitrypsin protein[1].

Target Condition: Alpha-1 Antitrypsin Deficiency (AATD)

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder that can lead to serious lung problems, particularly pulmonary emphysema. Emphysema is a condition where the air sacs in the lungs are damaged, making it difficult to breathe[1].

People with AATD don’t produce enough of a protein called Alpha-1 Antitrypsin (AAT), which protects the lungs from damage. Without enough AAT, the lungs become more susceptible to inflammation and destruction, leading to emphysema and other respiratory issues[1].

How SERPINA1(HUMAN)-AAV8-1 Works

SERPINA1(HUMAN)-AAV8-1 works by introducing a healthy copy of the SERPINA1 gene into the patient’s cells. This is done using a modified virus called AAV8, which serves as a delivery vehicle for the gene[1].

The therapy is administered through intravenous infusion, which means it’s given directly into the bloodstream. Once in the body, the AAV8 virus carries the SERPINA1 gene to the liver cells, where it can start producing the Alpha-1 Antitrypsin protein[1].

The goal of this treatment is to increase the levels of Alpha-1 Antitrypsin in the body, potentially slowing down or preventing further lung damage in people with AATD[1].

Current Clinical Trial Information

SERPINA1(HUMAN)-AAV8-1 is currently being studied in a Phase 1/2 clinical trial. This trial aims to evaluate the safety, tolerability, and effectiveness of the therapy in adults with AATD-associated lung disease[1].

The main objectives of the study include:

  1. Assessing the safety and tolerability of SERPINA1(HUMAN)-AAV8-1
  2. Evaluating how the therapy affects Alpha-1 Antitrypsin levels in the body (pharmacodynamics)
  3. Studying how the body processes the therapy (pharmacokinetics)
  4. Monitoring the immune response to the treatment
  5. Examining how the therapy impacts patients’ quality of life

The study will also look at how long the therapy remains in the body and whether it’s released in bodily fluids (a process called shedding)[1].

Eligibility Criteria

To participate in the clinical trial for SERPINA1(HUMAN)-AAV8-1, patients must meet certain criteria. Some key eligibility requirements include:

  • Age between 18 and 75 years
  • Diagnosed with AATD-associated lung disease
  • No significant liver problems
  • No recent history of serious heart conditions or stroke
  • No current infections or recent use of certain medications
  • Willingness to follow specific guidelines during the study, such as contraception requirements and restrictions on alcohol and smoking

It’s important to note that these are just some of the criteria, and the full list is more extensive. Potential participants should discuss their eligibility with their healthcare provider or the study team[1].

Safety Monitoring and Potential Side Effects

As with any new treatment, safety is a top priority in the clinical trial of SERPINA1(HUMAN)-AAV8-1. The study will closely monitor participants for any side effects or adverse reactions. Some areas of focus include:

  • Immune responses to the therapy
  • Changes in liver function
  • Any unexpected reactions to the treatment

Participants will undergo regular check-ups and tests throughout the study to ensure their safety and to gather important data about how the therapy works in the body[1].

Future Prospects and Considerations

SERPINA1(HUMAN)-AAV8-1 represents a potentially groundbreaking approach to treating AATD-associated lung disease. If successful, this gene therapy could offer a long-lasting solution for patients, potentially reducing or eliminating the need for ongoing treatments like protein replacement therapy[1].

However, it’s important to remember that the therapy is still in the early stages of clinical testing. More research is needed to fully understand its effectiveness, long-term safety, and potential impact on patients’ lives[1].

As research continues, patients with AATD and their healthcare providers should stay informed about the progress of this and other potential new treatments. While SERPINA1(HUMAN)-AAV8-1 shows promise, it’s crucial to approach new therapies with both hope and caution, always prioritizing patient safety and well-being[1].

Aspect Details
Drug Name NTLA-3001 (Serpina1(Human)-AAV8-1)
Trial Phase Phase 1/2
Condition Treated Alpha-1 Antitrypsin Deficiency (AATD)-associated lung disease
Main Objective Evaluate safety and tolerability
Secondary Objectives Assess pharmacodynamics, pharmacokinetics, immunogenicity, and quality of life impact
Administration Single intravenous infusion
Key Eligibility Criteria Adults 18-75 years, diagnosed AATD-associated lung disease, no prior gene therapy
Primary Endpoint Treatment-emergent adverse events (TEAE)
Key Secondary Endpoints Circulating AAT protein levels, antibody responses, vector shedding

FAQ

  • What is NTLA-3001 and how does it work? NTLA-3001 is a gene therapy drug that uses Serpina1(Human)-AAV8-1 to introduce a copy of the therapeutic transgene, wild-type SERPINA1, into patients with Alpha-1 Antitrypsin Deficiency (AATD)-associated lung disease. It aims to address the underlying genetic cause of the condition by providing a functional copy of the SERPINA1 gene.
  • Who is eligible for the NTLA-3001 clinical trial? Eligible participants are adults aged 18-75 with a diagnosis of AATD-associated lung disease. They must meet specific criteria, including having maximized or refused available standard care, and have no prior gene therapy or recent participation in other clinical studies.
  • What are the main objectives of the NTLA-3001 clinical trial? The main objectives are to evaluate the safety and tolerability of NTLA-3001 in adult participants with AATD-associated lung disease. Secondary objectives include assessing pharmacodynamics, pharmacokinetics, immunogenicity, and the effect on health-related quality of life.
  • How is NTLA-3001 administered to patients? NTLA-3001 is administered as a single treatment through intravenous infusion. Participants must agree to certain pretreatment medication regimens and postinfusion corticosteroid regimens as part of the study protocol.
  • What are the potential benefits and risks of participating in this clinical trial? Potential benefits include receiving a novel gene therapy that may address the underlying cause of AATD-associated lung disease. Risks may include treatment-emergent adverse events, which are being closely monitored as part of the study's primary endpoint. The trial also assesses immunogenicity and the body's response to the therapy to ensure patient safety.

Ongoing Clinical Trials on Serpina1(Human)-Aav8-1

  • Study on the Safety of NTLA-3001 for Adults with Alpha-1 Antitrypsin Deficiency-Related Lung Disease

    Not recruiting

    1 1
    Investigated drugs:
    Ireland

Glossary

  • Alpha-1 Antitrypsin Deficiency (AATD): A genetic disorder that results in low levels of alpha-1 antitrypsin protein in the blood, which can lead to lung and liver disease.
  • Gene Therapy: A technique that uses genes to treat or prevent disease by introducing functional genes into cells to replace faulty ones.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • AAV Vector: Adeno-Associated Virus vector, a tool used in gene therapy to deliver genetic material into cells.
  • Shedding: The release of viral vectors or genetic material from the body after gene therapy treatment.
  • SERPINA1 Gene: The gene responsible for producing alpha-1 antitrypsin protein, which is deficient in AATD patients.
  • Pulmonary Emphysema: A lung condition characterized by damage to the air sacs (alveoli) in the lungs, leading to breathing difficulties.
  • LNP: Lipid Nanoparticle, a delivery system used in some gene therapies to protect and transport genetic material.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-ntla-3001-for-adults-with-alpha-1-antitrypsin-deficiency-related-lung-disease/